Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, is issuing solicitation HT9402-26-Q-9103 to manage the purchase of pharmaceutical agents for the Military Health System. This requirement involves the establishment of Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on recommendations from the Department of Defense Pharmacy and Therapeutics Committee. The committee evaluates the relative clinical and cost-effectiveness of drugs to determine their classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. This acquisition is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 DRUGS AND BIOLOGICALS.

The scope of this solicitation includes the review of newly approved drugs such as Hyrnuo, Javadin, Komzifti, Lasix ONYU, Redemplo, and Starjemza during the February 2026 committee meeting. Performance is centered in San Antonio, Texas, under the direction of point of contact Tracy Banks. The notice includes 12 attachments, such as price lists for specific leukemia, antilipidemic, and diuretic agents, which were posted between December 11 and December 17, 2025. Following a pre-quotation teleconference on December 17, 2025, final responses to the solicitation must be submitted by January 5, 2026.